Financial Performance - The company's operating revenue for Q1 2025 was ¥175,735,762.62, a decrease of 26.35% compared to ¥238,622,168.70 in the same period last year[3] - The net profit attributable to shareholders was -¥6,001,192.11, representing a decline of 184.13% from a profit of ¥7,133,561.76 in the previous year[3] - Basic earnings per share decreased by 200.00% to -¥0.02 from ¥0.02 in the previous year[3] - Total revenue for Q1 2025 was RMB 175.74 million, a decrease of 26.4% compared to RMB 238.62 million in Q1 2024[16] - Net profit for Q1 2025 was a loss of RMB 5.89 million, compared to a profit of RMB 7.02 million in Q1 2024[17] - The company reported a total comprehensive loss of RMB 6.20 million in Q1 2025, compared to a comprehensive income of RMB 6.49 million in Q1 2024[17] Cash Flow and Operating Activities - The net cash flow from operating activities improved to ¥38,492,423.52, compared to -¥52,712,185.37 in the same period last year, indicating effective supply chain management[3] - Operating cash flow for Q1 2025 was RMB 38.49 million, a significant improvement from a negative cash flow of RMB -52.71 million in Q1 2024[19] - The company experienced a net cash outflow from investing activities of RMB 83.57 million in Q1 2025, compared to RMB -6.79 million in Q1 2024[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,552,107,798.54, an increase of 3.88% from ¥1,494,072,333.88 at the end of the previous year[6] - The company's current assets totaled RMB 1,321,354,869.58, compared to RMB 1,290,982,272.60 at the end of 2024, indicating an increase of about 2.4%[13] - Total liabilities rose to RMB 383,911,181.84 from RMB 319,439,793.98, marking an increase of approximately 20.2%[14] - The company's equity attributable to shareholders decreased to RMB 1,165,160,559.65 from RMB 1,171,469,561.57, a decline of about 0.5%[14] - The total current liabilities increased to RMB 380,399,337.40 from RMB 318,701,872.45, reflecting a growth of approximately 19.4%[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,527[10] - The company has not reported any changes in the top 10 shareholders or their participation in margin financing activities[12] Research and Development - Research and development expenses for Q1 2025 were RMB 635.17 thousand, a decrease of 30.6% from RMB 915.00 thousand in Q1 2024[16] Inventory and Receivables - The company reported a significant increase in inventory, which rose to RMB 208,529,372.68 from RMB 201,881,192.88, an increase of about 3.3%[13] - Accounts receivable increased to RMB 760,740,608.19 from RMB 738,471,128.95, representing a rise of approximately 3%[12] Non-Recurring Gains and Losses - Non-recurring gains and losses for the period totaled ¥43,497.32 after tax adjustments[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥6,044,689.43, a decline of 191.02% from ¥6,641,379.02 in the previous year[3] Equity and Return Metrics - The weighted average return on equity decreased to -0.51%, down 1.12 percentage points from 0.61% in the previous year[6] - The company's non-current assets totaled RMB 230,752,928.96, up from RMB 203,090,061.28, indicating an increase of approximately 13.6%[13]

证券代码：603122 证券简称：合富中国 公告编号：临 2025-016 公司新一届董事会、监事会换届选举工作完成前，公司第二届董事会和监事 会全体成员、董事会各专门委员会委员及高级管理人员将按照法律法规和《公司 章程》的规定继续履行职责和义务。 公司董事会及监事会延期换届不会影响公司正常生产经营。公司将积极推进 董事会、监事会换届选举工作进程，并按照相关规定及时履行信息披露义务。 二、独立董事任期届满辞任情况 根据《上市公司独立董事管理办法》、《公司章程》等相关规定，上市公 司独立董事占董事会成员的比例不得低于三分之一，独立董事在上市公司连 续任职时间不得超过六年。公司现任独立董事 Stanley Yi Chang 先生、雷 永耀先生以及周露露女士任期将于 2025 年 4 月 27 日届满且连任时间将满六 年。近日，公司董事会收到独立董事 Stanley Yi Chang 先生、雷永耀先生 以及周露露女士的辞呈，提请辞去独立董事及董事会下属专门委员会的相关 职务，辞职后 Stanley Yi Chang 先生、雷永耀先生、周露露女士将不再担 任公司的任何职务。具体辞任情况如下： 独立董事 Stanley ...

4月14日，合富中国今日收盘6.36元，上涨1.27%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到91.84倍，总市值25.32亿元。 从行业市盈率排名来看，公司所处的医药商业行业市盈率平均22.48倍，行业中值19.59倍，合富中国排 名第28位。 截至2024年年报，共有15家机构持仓合富中国，其中基金12家、其他3家，合计持股数509.24万股，持 股市值0.36亿元。 合富(中国)医疗科技股份有限公司的主营业务是从事以体外诊断相关的医疗设备及其耗材为主的国际贸 易、售后服务，贸易代理，从事医院信息管理系统的咨询服务以及相关配套服务。公司的主要产品是体 外诊断产品集约化业务、医疗产品流通。 来源：金融界 最新一期业绩显示，2024年年报，公司实现营业收入9.39亿元，同比-14.05%；净利润2756.63万元，同 比-41.58%，销售毛利率19.60%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)28合富中国91.8491.842.1625.32亿行业平均 22.4822.651.81105.57亿行业中值19.5916.211.3057.29亿1漱玉平民-106.04 ...

证券代码：603122 证券简称：合富中国 公告编号：临 2025-015 合富（中国）医疗科技股份有限公司 2025 年 1-3 月累计营业收入简报 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司 2025 年 1-3 月合并营业收入人民币 17,573.58 万元，较去年同期下降 26.35%，2025 年 1-2 月合并营业收入较去年同期下降 27.08%，下降幅度收窄 0.73%，营收情况持续改善。 特此公告。 合富（中国）医疗科技股份有限公司董事会 2025 年 4 月 11 日 1 合富（中国）医疗科技股份有限公司（以下简称"公司"）之间接控股股东 合富医疗控股股份有限公司（以下简称"合富控股"）为台湾地区证券柜台买卖 中心上柜公司，合富控股需按照台湾证券交易所相关规定，每月披露营业收入数 据。为使 A 股投资者能够及时了解公司的经营情况，本公司亦同步在上海证券交 易所指定的信息披露媒体《上海证券报》、《中国证券报》、《证券时报》、《证券日 报》和上海证券交易所网站（http://www.sse.com.cn ...

合富中国（603122）公告，公司2025年1-3月合并营业收入为人民币1.76亿元，同比下降26.35%。2025 年1-2月合并营业收入较去年同期下降27.08%，下降幅度收窄0.73%，营收情况持续改善。 ...

Group 1 - The core viewpoint of the articles indicates that 合富中国 (Hefei China) is experiencing a significant decline in stock price and financial performance, with a current PE ratio of 98.34, which is substantially higher than the industry average of 22.15 [1][2] - As of the 2024 annual report, 合富中国 reported a revenue of 939 million yuan, representing a year-on-year decrease of 14.05%, and a net profit of 27.57 million yuan, down 41.58% from the previous year [1] - The company operates primarily in the field of in vitro diagnostic medical devices and related consumables, with its main products being concentrated in the in vitro diagnostic product business and medical product distribution [1] Group 2 - The total market capitalization of 合富中国 is 2.711 billion yuan, with 15 institutions holding shares, including 12 funds, totaling 5.0924 million shares valued at 36 million yuan [1] - In terms of industry comparison, 合富中国 ranks 28th in terms of PE ratio within the pharmaceutical commercial sector, where the median PE ratio is 17.56 [1][2] - The sales gross margin for 合富中国 stands at 19.60%, indicating the profitability of its sales relative to its revenue [1]

Core Viewpoint - 合富中国 is transforming the medical supply chain industry by leveraging AI and digital transformation to enhance operational efficiency and resource allocation in healthcare [1][4]. Group 1: Company Development - 合富中国 was founded in 1997 in Shanghai and has evolved significantly over 28 years, becoming a leader in the medical supply chain sector [2]. - The company became a pioneer in providing refined management services for in vitro diagnostic reagents and consumables in 2008, helping hospitals reduce costs [2]. - In 2022, 合富中国 was listed on the Shanghai Stock Exchange, which has led to increased market competitiveness and brand recognition through joint ventures and acquisitions [3]. Group 2: ACME Empowerment Plan - The ACME empowerment plan, launched in early 2024, consists of four components: AI-assisted clinical diagnosis, an integrated hospital decision analysis platform, a digital platform for surgical education, and a medical integration and interaction platform [4]. - The ACME plan has shown significant results, including partnerships with major hospitals for AI-assisted diagnostic systems and the successful local production of surgical products [5]. Group 3: Future Strategy - The company aims to enhance its research and development in AI, expand market channels, and integrate the supply chain to adapt to tightening hospital budgets due to healthcare cost control policies [7]. - 合富中国 is actively pursuing partnerships and acquisitions to strengthen its position in the medical supply chain, exemplified by a recent collaboration with 晋弘科技 [7][8].

证券代码：603122 证券简称：合富中国 公告编号：临 2025-014 合富（中国）医疗科技股份有限公司 关于 2024 年年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 合富（中国）医疗科技股份有限公司（以下简称"公司"或"合富中国"） 于 2025 年 3 月 25 日（星期二）11:30-12:30 在价值在线网站（https://www.ir- online.cn/）通过网络文字互动的形式召开了公司 2024 年年度业绩说明会，现 将具体情况公告如下： 一、本次业绩说明会召开情况 公司于 2025 年 3 月 25 日（星期二）11:30-12:30 召开了公司 2024 年年度 业绩说明会，董事长 李惇先生、董事 总经理 财务总监（暂代）王琼芝女士、 独立董事 周露露女士、董事会秘书 朱莺女士出席了本次业绩说明会，与投资者 进行网络互动交流和沟通。本次业绩说明会召开前，公司已通过公司投资者关系 邮箱 ir_cowealth@cowealth.com 进行了提问预征集。 二、投资者提问 ...

海通证券股份有限公司关于合富（中国）医疗科技股份有限公司 首次公开发行股票并上市 之保荐总结报告书 | 保荐机构名称： | 海通证券股份有限公司 | | --- | --- | | 保荐机构编号： | Z22531000 | 经中国证券监督管理委员会《关于核准合富（中国）医疗科技股份有限公司首 次公开发行股票的批复》（证监许可[2021]4074 号）批复，合富（中国）医疗科技 股份有限公司（以下简称"上市公司"、"公司"或"发行人"）首次公开发行股票 99,513,200 股，每股面值人民币 1 元，每股发行价格人民币 4.19 元，募集资金总额 为人民币 416,960,308.00 元，扣除发行费用后，实际募集资金净额为人民币 359,690,993.41 元。本次发行证券已于 2022 年 2 月 16 日在上海证券交易所主板上市。 海通证券股份有限公司（以下简称"保荐机构"或"海通证券"）担任其持续督导保荐 机构，持续督导期间为 2022 年 2 月 16 日至 2024 年 12 月 31 日。 2024 年 12 月 31 日，持续督导期已届满，海通证券根据《证券发行上市保荐业 务管理办法》《上 ...

海通证券股份有限公司 关于合富（中国）医疗科技股份有限公司 2024 年度持续督导现场检查报告 （三）现场检查时间 2025 年 3 月 10 日至 2025 年 3 月 11 日 （四）现场检查人员 （二）保荐代表人 一、本次现场检查的基本情况 杨博文、陈邦羽 （一）保荐机构 海通证券股份有限公司 上海证券交易所： 经中国证券监督管理委员会《关于核准合富（中国）医疗科技股份有限公 司首次公开发行股票的批复》（证监许可〔2021〕4074 号）批复，合富（中国） 医疗科技股份有限公司（以下简称"合富中国"、"上市公司"、"公司"）首次公 开发行股票 9,951.32 万股，每股面值人民币 1 元，每股发行价格人民币 4.19 元， 募集资金总额为人民币 416,960,308.00 元，扣除发行费用后，实际募集资金净额 为人民币 359,690,993.41 元。本次发行证券已于 2022 年 2 月 16 日在上海证券交 易所上市。海通证券股份有限公司（以下简称"海通证券"、"保荐机构"）担任 其持续督导保荐机构，持续督导期间为 2022 年 2 月 16 日至 2024 年 12 月 31 日。 根据《证 ...